Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...

Antibody–drug conjugates (ADCs) represent a powerful therapeutic approach for the treatment of a range of cancers. They merge the toxicity of known chemical agents with the specificity of monoclonal ...

The clinical results from several trials suggest that patients get a high response rate from enfortumab vedotin (the antibody-drug conjugate) that is made durable from pembrolizumab (the checkpoint ...

An established but promising group of cancer drugs was a red-hot market in 2023, and more acquisitions and advancements are expected in the year ahead. That was one clear takeaway from the JPMorgan ...

Stability and toxicity are two of the major challenges. First, linker stability issues result in the immediate release of the drug payload following administration, which results in persistent high ...

Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. I am delighted to ...

Preliminary clinical results of the MYTHIC study will be presented, revealing for the first time data of the combination of WEE1 and PKMYT1 inhibition (zedoresertib and lunresertib) for the treatment ...